Gilead Sciences, Inc. (NASDAQ:GILD) is recognized among the 15 Best Passive Income Stocks to Buy Right Now. Scotiabank analyst Louise Chen sees opportunity in large-cap biopharma, maintaining an Outperform rating on GILD due to potential innovation in the sector. GILD remains a reliable dividend payer, with shares up 36% in 2025 and total revenue reaching $7.8 billion in Q3.

Gilead Sciences, Inc. (NASDAQ:GILD) has made strides in the oncology field, despite a 3% revenue decline in the third quarter. The company’s active oncology pipeline, larger than its HIV portfolio, is expected to drive sales higher with label expansions and new approvals in the cancer market. GILD remains a promising investment, but some AI stocks may offer greater upside potential.

While GILD shows promise as an investment, some AI stocks may offer better opportunities with less downside risk. For those seeking an undervalued AI stock with potential from Trump-era tariffs and onshoring trends, consider exploring the best short-term AI stock. Explore other investment opportunities with extreme dividend stocks and overlooked dividend stocks for a well-rounded portfolio.

Read more at Yahoo Finance: Scotiabank Analyst Sees Opportunity in Large Cap Biopharma, Keeps Outperform on GILD